MND Association

37th International Symposium on ALS/MND

Programme

9-11 December 2026
Amsterdam, the Netherlands



Hosts

ALS patiënten vereniging

ALS Centrum Nederland

ALS Stichting ALS Nederland

Organised by the
Motor Neurone Disease Association

MND Association

37th International Symposium on ALS/MND

Organiser of the symposium

Motor Neurone Disease Association
Francis Crick House, 6 Summerhouse Road, Northampton NN3 6BJ, UK
Tel: +44 1604 250505
Email: symposium@mndassociation.org
Website: mndassociation.org
symposium.mndassociation.org

Symposium Hosts

ALS patiënten vereniging

ALS Centrum Nederland

ALS Stichting ALS Nederland

alspatientenvereniging.nl
als-centrum.nl
als.nl

CPD/CME Accreditation

The 37th International Symposium on ALS/MND has been approved by the Federation of the Royal Colleges of Physicians of the United Kingdom for 18 category 1 (external) CPD credit(s)

Ethical MedTech Compliance Approval

The 37th International Symposium on ALS/MND has been approved as COMPLIANT by the Ethical MedTech Conference Vetting Service (CVS).

CVS APPROVED 2026 ETHICAL MEDTECH

Welcome to Amsterdam

The ALS Patient Association, ALS Centre Netherlands and ALS Foundation Netherlands warmly welcome you to the 37th International Symposium on ALS/MND. It is an honour to welcome you to this event, organised in collaboration with the MND Association. We look forward to inspiring days filled with meaningful encounters and new insights.

In the Netherlands, approximately 1,500 people live with ALS/MND. Each year, 500 people lose their lives to these diseases, and 500 people are newly diagnosed. Most patients receive their diagnosis at the ALS Centre in Utrecht. This centre of expertise offers a unique combination of diagnostics, care and scientific research. All in one place.

The ALS Patient Association, ALS Centre Netherlands and the ALS Foundation Netherlands are independent organizations that collaborate closely in the fight against ALS. Based on our own vision and expertise, we work towards our shared goal: a world without ALS/MND.

We are more hopeful than ever. The discovery of a treatment for two specific genetic forms of ALS shows that the disease will one day be treatable. But in the search for the cause and treatment of ALS, national and international collaboration is crucial.

This annual symposium brings together more than 1,000 people, including researchers, healthcare professionals, representatives of patient organizations and people living with ALS, to share their knowledge about ALS. This is essential for finding a solution to these relentless diseases. When people join forces, plans are made and results are achieved.
The Dutch are pragmatic and curious by nature. We believe in innovation and continuous learning and approach the world with an open mind. As a small country, we are used to looking beyond our borders in search of opportunities and meaningful encounters. During your visit to Amsterdam, we encourage you to embrace the Dutch spirit: explore with curiosity, act with pragmatism, and welcome every opportunity for meaningful exchange.

We look forward to meeting you here in Amsterdam. Please take some time to explore our capital city. Let yourself be inspired by its beautiful canals, famous museums and rich history. Return home full of energy to continue working with us on a world free of ALS/MND.

Age Veenstra
Chairman,
ALS Patient Association

Leonard van den Berg
Director and founder,
ALS Centre Netherlands

Limore Noach
CEO,
ALS Foundation Netherlands



Foreword

Welcome to the 37th International Symposium on ALS/MND.

For the first time since my initial Symposium attendance in 1994, it is returning to the Netherlands, this time in Amsterdam. I am sure you will greatly enjoy exploring this historic, fascinating city, famous for its UNESCO-listed 17th-century canal ring comprising about 100 km of water in 165 canals and crossed by more than 1200 bridges. Amsterdam's canals are the site of the Annual City Swim to raise funds for ALS research, held every year in September. This year more than 3000 swimmers undertook the 2 km swim, including 12 with ALS, and raised more than €3 million for ALS/MND research.

Amsterdam is famous for many things, including the Rijksmuseum with The Night Watch, the van Gogh museum, and Anne Frank House, and the Netherlands more broadly for pancake houses, rijstaffel, trams, cycling, tulips, windmills and much more. But perhaps most importantly, without the Netherlands, there would be no medical training the way we have it today. In the late 1600s, Herman Boerhaave, a professor at Leiden, developed the structured curriculum of medical education now used worldwide, in which there is a premedical phase teaching basic sciences, a preclinical phase covering pathology, anatomy and pharmacology, and then a clinical phase with direct patient contact.

Our Symposium this year is similarly structured around fundamental science, preclinical science and clinical work. We have sessions on proteostasis, genetics, cell biology and the role of glia, through to organoids, RNA dysregulation, and the role of the immune system, as well as biomarkers, cognitive and behavioural changes, PLS, and clinical trials.

On the back of an effective treatment for people with SOD1-ALS, and now promising results with FUS-ALS, the Symposium draws us together to share our knowledge, expertise and resources, accelerating the search for an effective treatment for all ALS/MND. I wish you all a very informative and enjoyable meeting.

Ammar Al-Chalabi
Programme Committee Chair

Programme

Wednesday 9 December

SESSION 1

Joint Opening Session

Location: Auditorium

Live stream session

Chairs: **A Al-Chalabi (UK), B Dickie (UK)**

08:30 – 08:35	Welcome – **A Al-Chalabi (UK) and B Dickie (UK)**
08:35 – 08:45	Welcome from Stichting ALS Nederland/ALS Centrum Nederland/ALS Patiënten Vereniging – **L Noach (Netherlands)**
08:45 – 09:25	C1 Stephen Hawking Memorial Lecture: Toward therapy for ALS: SOD1 and beyond – **R Brown (USA)**
09:25 – 09:30	Drs. Ayeez and Shelena Lalji and Family ALS Endowed Award for Innovative Healing
09:30 – 09:40	International Alliance Forbes Norris Award
09:40 – 10:00	IPG Award and winner's research presentation

10:00 – 10:30 **Refreshments and networking**
Onyx Lounge, Auditorium Lounge, Forum Lounge

Exhibitors
Onyx Lounge

SESSION 2A

Clinical Trials

Location: Auditorium

Chairs: **J Andrews (USA), P Van Damme (Belgium)**

10:30 – 10:45

C2 Safety and efficacy of lithium carbonate for patients with ALS homozygous for the C-allele at SNP rs12608932 in UNC13A: Results for a Phase 3 randomised double-blind, placebo-controlled trial **S Willemse (Netherlands)**

10:45 – 11:00

C3 Efficacy and tolerability of β-hydroxybutyrate in patients with ALS (KETO-ALS): A randomised, placebo-controlled, double-blind study **J Dorst (Germany)**

11:00 – 11:15

C4 VHB937 efficacy and safety in people with ALS: Primary results from the double-blind, randomized, placebo-controlled phase 2 ASTRALS trial **L van den Berg (Netherlands)**

SESSION 2B

Genetics

Location: Forum

Chairs: **J Cooper-Knock (UK), J Heckmann (South Africa)**

10:30 – 11:00

C10 Motor neuron disease / amyotrophic lateral sclerosis in India: Emphasis on genetic landscape **A Nalini (India)**

11:00 – 11:15

C11 Genotype-phenotype correlations in over 500 patients with TARDBP-related ALS/FTD: Results from a new research cohort and comprehensive literature review **E Harrington (USA)**

11:15 – 11:30

C12 Oligogenic action of pleiotropic neurodegenerative repeat expansions in ALS **G Venslovaite (Ireland)**

11:15 – 11:30

C5 Extended survival results from DAZALS: A phase 2 randomized controlled trial of Dazucorilant, a selective glucocorticoid receptor modulator, in ALS
L van den Berg (Netherlands)

11:30 – 11:45

C6 Healey ALS MyMatch: Digoxin in ACACIA trial and rapid drug purposing in ALS
S Babu (USA)

11:45 – 12:00

C7 Metformin shows favourable safety and reduces RAN proteins, markers of neurodegeneration and neuroinflammation in C9orf72 ALS patients in a Phase 2 open-label clinical trial **L Ranum (USA)**

12:00 – 12:15

C8 FUSION, a phase 1-3 clinical trial of ulefnersen in people with ALS with fused in sarcoma variants (FUS-ALS) **N Schneider (USA)**

12:15 – 12:30

C9 Results from ANQUR: a Phase 1/2b MAD and Dose-Range Finding Study to Assess Safety, Tolerability, Pharmacokinetics, and Efficacy of QRL-201, A STMN2 Targeting Splice-Switching ASO for the Treatment of Sporadic and C9orf72 ALS
L van den Berg (Netherlands)

11:30 – 11:45

C13 Genetic variants related to a familial C9orf72 penetrance score in FTD and ALS
N Dehghani (USA)

11:45 – 12:00

C14 Retrotransposons: A new era for novel sources of genetic risk for neurodegenerative disorders **B Middlehurst (UK)**

12:00 – 12:15

C15 Hidden viral signatures in ALS: Locus-specific transcriptomics reveals dysregulated human endogenous retrovirus loci
N Sai (Australia)

12:15 – 12:30

C16 Sex-specific DNA methylation differences in ALS **Y Kim (UK)**

12:30 – 14:00 **Lunch and networking**
Auditorium Lounge, Forum Lounge

Exhibitors
Onyx Lounge

SESSION 3A

Proteostasis

Location: Auditorium

Chairs: **L van den Bosch (Belgium), S Pozzi (Canada)**

14:00 – 14:30

C17 Physiological and pathological roles of phase separation **D Dormann (Germany)**

SESSION 3B

Transitioning from Phase 2 to Phase 3 in ALS Clinical Trials:

C22 Balancing Signals of Biological Activity, Clinical Efficacy, and Uncertainty

Location: Forum

Chairs: **L Bruijn (UK), M Harms (USA)**

14:00 – 14:15

R van Eijk (Netherlands)

14:15 – 14:30

S Paganoni (USA)

SESSION 3C

Neuroimaging

Location: E103 – E108

Chairs: **P-F Pradat (France), E Pioro (Canada)**

14:00 – 14:30

C23 Imaging prodromal ALS
H-J Westeneng (Netherlands)

14:30 – 14:45

C24 C9orf72 specific hypothalamic atrophy precedes ALS-FTD phenoconversion
N Schweitzer (USA)

14:30 – 14:45
C18 Cryo-EM atomic pathology of ALS and associated diseases
A Giblin (UK)

14:45 – 15:00
C19 Distinct routes to abnormal TDP-43 oligomerisation in C9orf72 and sporadic ALS
T Shelkovnikova (UK)

15:00 – 15:15
C20 Cytoplasmic TDP-43 alters neuronal lysosome localisation, transport, cargoes and degradation capacity in ALS
S Keating (Australia)

15:15 – 15:30
C21 Cystatin C and Bunina bodies as novel drivers of TDP-43 proteinopathy in ALS
S Granger (UK)

14:30 – 14:45
M Barlow (UK)

14:45 – 15:00
T Cochrane (USA)

15:00 – 15:30
Q&A/Panel Discussion

14:45 – 15:00
C25 Functional connectivity outperforms regional metrics as a trial-ready resting state fMRI biomarker in ALS: A multicenter longitudinal validation
P Parnianpour (Canada)

15:00 – 15:15
C26 Estimated monthly rate of spinal cord atrophy (EMSA): A spinal cord single-scan imaging marker for survival prediction in ALS
M Wendebourg (Switzerland)

15:15 – 15:30
C27 Combined [18F]SynVesT-1 PET imaging and CSF levels identify SV2A as a multimodal biomarker for synaptic dysfunction in ALS
F Hobin (Belgium)

15:30 – 16:00 **Refreshments and networking**
Onyx Lounge, Auditorium Lounge, Forum Lounge

Exhibitors
Onyx Lounge

SESSION 4A
Glia
Location: Auditorium
Chairs: **M Milanese (Italy), H Inoue (Japan)**

16:00 – 16:15
C28 Astrocyte dysfunction distinguishes monozygotic twin C9orf72 expansion carriers discordant for ALS
A Shaw (UK)

16:15 – 16:30
C29 Glial hnRNP network dysregulation reveals distinct RNA processing signatures across sporadic and C9orf72-associated FTLD-TDP **A Gatt (UK)**

SESSION 4B
ALS-FTD
Location: Forum
Chairs: **E Rogaeva (Canada), J Rohrer (UK)**

16:00 – 16:40
C34 Will that be three lumps or one? The conundrum of defining ALS, ALS-FTSD and FTD as a single entity
J Robertson (Canada), M Strong (Canada)

16:40 – 17:10
C35 The FTD/ALS proteins Annexin A11 and CHMP2B act sequentially in plasma membrane repair
A Isaacs (UK)

SESSION 4C
Optimising Care
Location: E103 – E108
Chairs: **S Feldman (USA), C McDermott (UK)**

16:00 – 16:15
C36 The Rapid Access ALS Clinic model: A step towards addressing ALS diagnostic delay **K Gwathmay (USA)**

16:15 – 16:30
C37 Decoding healthcare complexity in ALS: A multidimensional analysis of resource allocation and predictive drivers at hospital admission **F Cerri (Italy)**

16:30 – 16:45

C30 ALS-FTD-linked CCNFS621G drives increased hippocampal astrocyte ramification and mitochondrial dysfunction, and impairs motor neuron excitability **L Ooi (Australia)**

16:45 – 17:00

C31 Disrupted RNA binding protein network in oligodendrocytes rewires neuronal epigenome and leads to cognitive impairment in ALS **L Dupuis (France)**

17:00 – 17:15

C32 An activation continuum governing oligodendrocyte vulnerability in the human central nervous system
M Georgopolou (Belgium)

17:15 – 17:30

C33 Oligodendrocyte dysfunction as an active contributor to ALS/MND: A three phase disease trajectory driven by TDP-43 mislocalisation
T Atienzar (UK)

17:10 – 17:30

Q&A/Panel Discussion

16:30 – 16:45

C38 Health outcomes research in ALS: Social determinants of health enrich real-world data
M Galvin (Ireland)

16:45 – 17:00

C39 Cost-effectiveness of multidisciplinary care in ALS: Survival gains at what cost?
S Hundai (Canada)

17:00 – 17:15

C40 Complex relationships: People living with MND and family perspectives of homecare **E Wilson (UK)**

17:15 – 17:30

C41 Momentary perceptions of care for ALS caregivers: assessing day-to-day well-being in young carers
M Kavanaugh (USA)

Poster Session A

Location: Europa Foyer

17:45 – 19:30

Theme 1	Epidemiology and informatics
Theme 2	Genetics and genomics
Theme 3	In vitro experimental models
Theme 7	Pre-clinical therapeutic strategies
Theme 10	Disease stratification and phenotyping
Theme 11	Cognitive and psychological assessment and support
WIP	Biomedical work in progress
WIP	Care practice work in progress

Thursday 10 December

SESSION 5A

Organoids

Location: Auditorium

Chairs: **N Maragakis (USA), A Catanese (Germany)**

08:30 – 09:00

C42 Cystic fibrosis organoids for precision medicine: Lessons for other diseases. **J Beekman (Netherlands)**

09:00 – 09:30

C43 Neural organoids as human models for investigating ALS pathogenesis and therapeutic discovery **J Pasterkamp (Netherlands)**

09:30 – 09:45

C44 A human corticospinal organoid-slice connectoid model for early mechanistic and therapeutic discoveries in ALS **A Lakatos (UK)**

09:45 – 10:00

C45 Deciphering the epigenetic and transcriptomic landscape of traumatic injury in asymptomatic C9orf72 mutation carriers using hiPSC-derived organoids **K Baskar (Germany)**

SESSION 5B

Metabolism and Nutrition

Location: Forum

Chairs: **H Stavroulakis (UK), F Steyn (Australia)**

08:30 – 09:00

C46 Metabolic changes in ALS: Linking metabolism, disease progression and therapeutic targets **S Ngo (Australia)**

09:00 – 09:15

C47 Characterizing energy metabolism among people with ALS and pathogenic gene carriers **I Lee (USA)**

09:15 – 09:30

C48 Resting blood lactate predicts survival and weight loss in ALS: An international exploratory-validation study **R Nakamura (Australia)**

09:30 – 09:45

C49 A lean phenotype in C9orf72 repeat-expansion carriers does not explain ALS penetrance: an analysis of data from the UK Biobank **A Strange (UK)**

09:45 – 10:00

C50 Characterising microbial markers predictive for ALS onset and progression **C Jaing (USA)**

SESSION 5C

Clinical Electrophysiology

Location: E103 – E108

Chairs: **M Weber (Switzerland), J Alix (UK)**

08:30 – 08:45

C51 Cortical drive index: Bilateral cortical excitability at diagnosis and survival in ALS' **M Conwill (UK)**

08:45 – 09:00

C52 The ALS Methodology Natural History Study: A longitudinal head-to-head comparison of electrophysiological and clinical outcome measures **B Scodari (USA)**

09:00 – 09:15

C53 Advancing MScan-MUNE as an endpoint for clinical trials in ALS: Recommendations to minimize floor effects in phase 2 trials **D Garcia (Netherlands)**

09:15 – 09:30

C54 Fasciculation frequency behaviour and ALS progression: A clinical-neurophysiological study. **M Santos (Portugal)**

09:30 – 09:45

C55 Longitudinal decline in beta-band EEG power tracks ALS progression **S Dukic (Netherlands)**

09:45 – 10:00

C56 Disease-specific aperiodic EEG exponent signatures reflect distinct cortical excitation-inhibition imbalance across neurodegeneration: ALS as a uniquely identifiable pattern **K-D Tran (Singapore)**

10:00 – 10:30

Refreshments and networking

Onyx Lounge, Auditorium Lounge, Forum Lounge

Exhibitors

Onyx Lounge

SESSION 6A

Preclinical Therapeutic Strategies

Location: Auditorium

Chairs: **F Ducotterd (UK), R Mead (UK)**

10:30 – 10:45

C57 A multi-target combination approach to novel therapeutic strategy in C9orf72-ALS **M Cattaneo (Italy)**

10:45 – 11:00

C58 Novel brain-penetrating peptides restore autophagy and confer therapeutic benefit in ALS **A Amin (Australia)**

11:00 – 11:15

C59 ACE-2223, a first-in-class oral small molecule for sporadic ALS, treats both gain- and loss-of-function TDP-43 pathology, extends survival and decreases NfL in mice **K Planey (USA)**

11:15 – 11:30

C60 SYF2-targeting antisense oligonucleotides correct TDP-43 pathology and rescue motor neurons: In vivo proof-of-concept and early safety for a novel ASO program in ALS/FTD **W-H Chang (USA)**

11:30 – 11:45

C61 Splice-correcting KCNQ2 and UNC13A therapies rescue paradoxical hyperexcitability and synaptic failure in TDP-43 ALS/FTD **P Harley (UK)**

11:45 – 12:00

C62 ENGRAILED-1 restores motor neuron survival and function in ALS models: Evidence for a homeoprotein signaling deficit in disease. **A Prochiantz (France)**

SESSION 6B

ALS/MND Heterogeneity

Location: Forum

Chairs: **T Heiman-Paterson (USA), L van den Berg (Netherlands)**

10:30 – 11:00

C65 Why is deep phenotyping important? **T Meyer (Germany)**

11:00 – 11:15

C66 What do ALS motor phenotypes measure? A population-based decomposition of the OPM classification's prognostic dimensions **A Chio (Italy)**

11:15 – 11:30

C67 Stratification and prognosis prediction for patients with ALS: Development and validation of a phenotyping strategy **J Zhang (China)**

11:30 – 11:45

C68 Identifying phenotypic subgroups with distinct prognostic profiles in early-stage ALS using multidimensional clinical features: Results from a Chinese cohort **Y Tan (China)**

11:45 – 12:00

C69 Muscle proteins in plasma associates with distinct phenotypes in ALS **L Azizi (Sweden)**

12:00 – 12:15

C70 Neurobiological basis of bulbar involvement in ALS phenotypic heterogeneity **S Marcuzzo (Italy)**

12:15 – 12:30

C71 Correlating clinical heterogeneity with cellular phenotypes in an expanded cohort of C9orf72-ALS induced neural progenitor cells (iNPCs) **A Shaw (UK)**

SESSION 6C

Epidemiology

Location: E103 – E108

Chairs: **E Pupillo (Italy), S Goutman (USA)**

10:30 – 11:00

C72 How can we identify and quantify the environmental component of ALS risk? **F Fang (Sweden)**

11:00 – 11:15

C73 Exposome-wide association study (ExWAS) in ALS **I van Wijk (Netherlands)**

11:15 – 11:30

C74 Use of muscle relaxants is associated with higher incidence of ALS: A cohort study from the UK Biobank and systematic review **J-H Deng (China)**

11:30 – 11:45

C75 Statin use and risk of ALS among U.S. military veterans: A large nested case-control study **M Weisskopf (USA)**

11:45 – 12:00

C76 The risk of ALS in a large cohort of male UK former professional footballers **E Pupillo (UK)**

12:00 – 12:15

C77 Founder-related genetic structure shapes geographic variation in ALS mortality in Finland **H Hokkanen (Finland)**

12:15 – 12:30

C78 Examining the age-incidence curves of ALS across European registers **R McFarlane (Ireland)**

12:00 – 12:15

C63 Systemic administration of a cell-internalizing CYTOPE® targeting pTDP-43 reduces CNS intraneuronal pathology in a mouse model of TDP-43 proteinopathy **S Tam (USA)**

12:15 – 12:30

C64 AAV-mediated gene augmentation therapy for NEK1-ALS **K Meijboom (USA)**

12:30 – 12:45

C64A Advancing ALS and FTD Treatment: A Vaccine and Biomarker Approach Targeting HERV-K Env **M Garcia-Montojo (USA)**

12:30 – 14:00 **Lunch and networking**
Auditorium Lounge, Forum Lounge

Exhibitors
Onyx Lounge

SESSION 7A

RNA Dysregulation

Location: Auditorium

Chairs: **M Hallegger (UK), B Rojelj (Slovenia)**

14:00 – 14:15

C79 Modelling RNA-binding protein loss-of-function in human iPSC neurons and assembloids to identify MND-relevant RNA processing signatures and targetable splice events **M White (UK)**

14:15 – 14:30

C80 ALS4 associated senataxin mutation disrupts R-loop dependent local and distal transcriptional regulation in human motor neurons **J Bussgang (USA)**

14:30 – 14:45

C81 Unravelling the relationship between tau dysregulation and RNA-binding protein dysfunction in C9orf72-ALS **T Petrozziello (USA)**

SESSION 7B

Presymptomatic and Early Disease Markers

Location: E103 – E108

Chairs: **C Ingre (Sweden), J Berry (USA)**

14:00 – 14:15

C85 From compensation to collapse: Elucidating the biology of pre-symptomatic ALS **M Benatar (USA)**

14:15 – 14:30

C86 Associations between pre-diagnosis plasma neurofilament light polypeptide and ALS risk in the Danish EPIC cohort **A Davies (USA)**

14:30 – 14:45

C87 Spatiotemporal transcriptomics reveals early dysregulation in pre-symptomatic ALS skin **H Spence (UK)**

SESSION 7C

Assistive Technology

Location: Forum

Chairs: **J Chudge (UK), J Bedford (UK)**

14:00 – 14:15

C91 Rewriting the future of disability. **B Muller (Netherlands)**

14:15 – 14:30

C92 Implantable BCI devices for at-home use: Challenges and impact **M Vansteensel (Netherlands)**

14:30 – 14:45

C93 Ultra-fast, non-invasive brain-computer interfaces for real-time control **R Muresan (Romania)**

14:45 – 15:00

C94 Innovation to unlock creative expression. Exploring a new form of accessible, scalable, non-invasive brain-computer interface. **A Knight (Netherlands/Japan)**

14:45 – 15:00

C82 ALS causative gene ARPP21 drives TDP-43 proteinopathy and assembles into dynamic RNA granules
A Aabdien (UK)

15:00 – 15:15

C83 A natural antisense lncRNA at the TBK1 locus defines a novel regulatory layer and potential therapeutic target in TBK1-ALS **H Kinsella (Spain)**

15:15 – 15:30

C84 TDP-43 dysfunction induces cryptic circular RNAs in ALS/FTD **F Pellegrini (UK)**

14:45 – 15:00

C88 MYL1 but not NfL is changed in CSF of presymptomatic ALS mutation carriers
B Muqaku (Germany)

15:00 – 15:15

C89 Evaluating the viability of serum chitotriosidase as a minimally invasive diagnostic biomarker for early stage sporadic ALS
S Narasappa (India)

15:15 – 15:30

C90 A two-step blood neurofilament algorithm for biomarker-supported diagnosis of ALS
J Dubin (Belgium)

15:00 – 15:30

Q&A/Panel Discussion

15:30 – 16:00 **Refreshments and networking**
Onyx Lounge, Auditorium Lounge, Forum Lounge

Exhibitors
Onyx Lounge

SESSION 8A

Immunity and Neuroinflammation

Location: Auditorium

Chairs: **M Morsch (Australia), C Henstridge (UK)**

16:00 – 16:15

C95 Immune stimulation exacerbates cell autonomous microglial dysfunction in a stem cell model of TBK1-associated ALS-FTD
U Chughtai (UK)

16:15 – 16:30

C96 Progressive microglial and synaptic dysfunction in a novel mouse model of TBK1-associated frontotemporal dementia
V Gerbino (Italy)

SESSION 8B

Primary Lateral Sclerosis and Upper Motor Neuron Degeneration

Location: Forum

Chairs: **S Paganoni (USA), M van Es (Netherlands)**

16:00 – 16:30

C101 From genes to therapies for the hereditary spastic paraplegias
C Blackstone (USA)

16:30 – 16:45

C102 Rate of disease progression, diagnostic change and biomarkers in Primary Lateral Sclerosis: 2-year follow up of the PLS Natural History Study cohort
I Lee (USA)

SESSION 8C

Respiratory Management

Location: E103 – E108

Chairs: **A Calvo (Italy), D Berlowitz (Australia)**

16:00 – 16:30

C106 Assessment and management of upper airway dysfunction during respiratory therapies in ALS
T Andersen (Norway)

16:30 – 16:45

C107 A data-driven respiratory reserve index predicts survival after NIV initiation in ALS **F Cerri (Italy)**

16:30 – 16:45

C97 A novel human motor neuron-microglia co-culture model identifies candidate neuroimmune responses to neuronal TDP-43 pathology
L Nikel (UK)

16:45 – 17:00

C98 Microglia-sufficient spinal organoids effectively model ALS and elucidate neuro-immune crosstalk
S Liu (Singapore)

17:00 – 17:15

C99 Lower and upper motor neuron clinicopathology driven by nerve injury and neuroinflammation are viable therapeutic targets in ALS
J Loeb (USA)

17:15 – 17:30

C100 IFN-1 signalling disrupts neuron-glia lipid metabolic coupling in MND
C Low (Australia)

16:45 – 17:00

C103 Diagnostic revision from PLS to ALS: A cohort study **E de Boer (Netherlands)**

17:00 – 17:15

C104 Metabolomic analysis of serum and plasma samples isolated from ALS and PLS patients begins to reveal key metabolite signatures for upper motor neuron vulnerability in MNDs
H Ozdinler (USA)

17:15 – 17:30

C105 Cervical spinal cord MRI and lateral column pallor reflect upper motor neuron burden across the PLS spectrum, independently of disease duration
T Shaw (Australia)

17:30 – 17:40

Awards:
The Thurza Campbell Award for Basic Science Innovation in PLS

The Marren Family Award for Clinical Innovation in PLS

16:45 – 17:00

C108 Point of care diaphragm ultrasound as a novel predictor of respiratory dysfunction in ALS: A prospective, longitudinal study **D Ta (Canada)**

17:00 – 17:15

C109 A longitudinal, mixed methods, real world evaluation of the implementation of remote monitoring of respiratory function to support clinical care in ALS **L Musson (UK)**

17:15 – 17:30

C110 Effects of combined lung volume recruitment and expiratory strength training on pulmonary and cough function in people living with ALS **L Gray (USA)**

Poster Session B

Location: Europa Foyer

17:45 - 19:30

Theme 4	In vivo experimental models
Theme 5	Human cell biology and pathology (including iPSC studies)
Theme 6	Tissue biomarkers
Theme 8	Clinical imaging and electrophysiology
Theme 9	Clinical trials and trial design
Theme 12	Clinical management and support
Theme 13	Primary lateral sclerosis and upper motor neurone degeneration

Friday 11 December

07:00 – 08:30 **Industry sponsored breakfast session** **(Non-CME)**

Location: E103 – E108

Drug Repurposing in ALS/MND: How Preclinical Drug Development Can Improve Translation

Faculty: A Walker (Australia); B Wainger (USA); J Connell (UK); K Mayl (UK); P Lingor (Germany); R Mead (UK)

SESSION 9A

Cell Heterogeneity and Profiling

Location: Auditorium

Chairs: **E Hedlund (Sweden), J Humphrey (USA)**

08:30 – 08:45

C111 Molecular subtypes in ALS: How the diversity of disease mechanisms could inform precision medicine approaches in clinical trials **P Lingor (Germany)**

08:45 – 09:00

C112 Altered age-dependent somatic mutational trajectories in ALS motor cortex neurons **Li Liu (Netherlands)**

09:00 – 09:15

C113 Molecular correlates of TDP-43 pathology in human motor neurons revealed by spatial transcriptomics **R De Souza (UK)**

09:15 – 09:30

C114 Spatial transcriptomic profiling reveals stage-dependent molecular responses to TDP-43 pathology in C9orf72-associated ALS **J Gregory (UK)**

09:30 – 09:45

C115 Splitformer -V2 predicts multi-tissue RNA splicing and nominates ALS-associated splice-altering variants. **M Zhang (China)**

09:45 – 10:00

C116 Subcellular transcriptomic signatures of C9orf72 and TARDBP mutations in hiPSC-derived motor neurons. **G Akbalik (USA)**

SESSION 9B

Harnessing Technological Innovation

Location: Forum

Chairs: **E Hobson (UK), D Murray (Ireland)**

08:30 – 08:45

C117 MND Alert: An electronic decision-support tool to support primary care practitioners with earlier detection and diagnosis of MND **C Gates (UK)**

08:45 – 09:00

C118 Designing and developing an intelligent chatbot to enhance personal insights related to Quality of Life based on the ALS/MND Personal Needs Matrix **J Chudge (UK)**

09:00 – 09:15

C119 Using digital services to support care pathways in MND: A mixed-methods process evaluation and economic analysis **L Knox (UK)**

09:15 – 09:30

C120 Impact of hybrid assistive limb on gait ability and quality of life in patients with ALS **O Kano (Japan)**

09:30 – 09:45

C121 User expectations and experiences with eye-control glasses for complex power wheelchairs in people with ALS: A multicentre observational study. **R Schiemann (Germany)**

09:45 – 10:00

C122 BCI-Augmented AAC in the home: A 3-5 month adaptive feasibility study of an EEG -enhanced Vision Pro system for Users with Motor and Speech Disabilities **C Ullrich (USA)**

10:00 – 10:30 **Refreshments and networking**

Onyx Lounge, Auditorium Lounge, Forum Lounge

Exhibitors

Onyx Lounge

SESSION 10A

Cell Biology and Pathology

Location: Auditorium

Chairs: **C Vance (UK), S Saxena (USA)**

10:30 – 10:45

C123 AI-based identification of TDP-43 molecular and clinical subgroups in ALS/FTD by population iPS and large-scale human autopsy analytics **J Rothstein (USA)**

10:45 – 11:00

C124 A high-affinity peptide nucleic acid aptamer enables cross-platform detection of TDP-43 from cells to biofluids **J Gregory (UK)**

11:00 – 11:15

C125 Network synchrony disrupted upon TDP-43 loss is rescued by antisense oligonucleotides which prevent UNC13A cryptic exon inclusion **E Ryadnov (UK)**

11:15 – 11:30

C126 Age and ALS-dependent RANBP17 decline unlocks a TDP-43 vicious cycle **G Haim (Israel)**

11:30 – 11:45

C127 Shared and disease-specific alterations of nucleocytoplasmic transport in physiological aging and ALS **A Juers (Germany)**

11:45 – 12:00

C128 Investigating SRSF1-interfering gene therapy for treatment of sporadic ALS **M Myszczynska (UK)**

12:00 – 12:15

C129 ARPP21 defines a TDP-43-independent aggregation pathway in ALS **D Campos-Melo (Canada)**

SESSION 10B

Cognitive and Behavioural Change

Location: Forum

Chairs: **C Shoesmith (Canada), E Mioshi (UK)**

10:30 – 10:45

C131 Cognitive/behavioural impairment definition in ALS: An international survey on current methodologies and consensus criteria **P Ferraro (Italy)**

10:45 – 11:00

C132 Cognition, behaviour, and mood in an Indian ALS cohort: A cross-sectional observational study using multiple screening instruments and clinical correlates **M Keerthipriya (India)**

11:00 – 11:15

C133 Optimized classification of cross-sectional and longitudinal cognitive screening in ALS **F Hiemstra (Netherlands)**

11:15 – 11:30

C134 Behavioural reserve in ALS: Premorbid, socio-educational and biological determinants of behavioural impairment **A Calvo (Italy)**

11:30 – 11:45

C135 Identifying mild cognitive impairment in presymptomatic ALS: ECAS vs comprehensive assessment **C McHutchinson (UK)**

11:45 – 12:00

C136 Cognition and behaviour in ALS (CABIA): Digital tools for early detection **R Convery (UK)**

SESSION 10C

Biomarkers

Location: E103 – E108

Chairs: **V Bonetto (Italy), P Corcia (France)**

10:30 – 11:00

C139 Lipids in ALS: Driver, modifier or bystander? **A Thompson (UK)**

11:00 – 11:15

C140 Whole blood RNA-seq identifies diagnostic and prognostic signatures and therapeutic candidates for ALS **Y Zhao (USA)**

11:15 – 11:30

C141 ERACE (Emory Rapid Access Clinical Evaluation) 10-protein model predicts ALS from plasma with high accuracy **E Thomas (USA)**

11:30 – 11:45

C142 Identification of plasma and CSF biomarkers to predict ALS disease progression **L Fichter (France)**

11:45 – 12:00

C143 Plasma and CSF prognostic biomarkers to predict ALS disease progression **J Berry (USA)**

12:00 – 12:15

C144 Proteomic convergence across blood and brain tissues in ALS **R Tan (Australia)**

12:15 – 12:30

C145 Exploring TDP-43 - related fluid biomarkers as indicators of ALS progression: A 12-month longitudinal study. **M Chatterjee (Netherlands)**

12:15 – 12:30

C130 FUS misfolding extends beyond FUS-ALS and increases with age across multiple ALS subtypes
F Waldron (UK)

12:00 – 12:15

C137 CognoMND: Development and evaluation of a remote speech-analysis platform for automated cognitive screening in ALS
L Ing (UK)

12:15 – 12:30

C138 The FTD Toolkit: A co-designed psychoeducational intervention for carers and healthcare professionals navigating the FTD-MND spectrum **A Trucco (UK)**

12:30 – 13:30 **Lunch and networking**
Auditorium Lounge, Forum Lounge

Exhibitors
Onyx Lounge

SESSION 11

Joint Closing Session

Location: Auditorium

Chairs: **A Al-Chalabi (UK), M Turner (UK)**

13:30 – 13:35	Invitation to Dublin 2027
13:35 – 13:45	Poster Prizes
13:45 – 13:55	C146 The Global MND Research Roundtable – **B Sheean (Australia)**
13:55 – 14:30	Review of the Year – **J Veldink (Netherlands)**
14:30 – 14:40	Sean M Healey International Prize for Innovation in ALS
14:40 – 15:10	C147 Understanding heterogeneity in ALS: From Artificial Intelligence to Precision Therapeutics – **C Yeo (Singapore)**
15:10 – 15:20	Late breaking news

Summary of events and locations

Tuesday 8 December

08:00 – 09:00	ALS-FTD Journal Editorial Board Meeting (closed meeting)	E102	1st
09:00 – 12:30	WFN ALS/MND Specialty Group	E107/E108	1st
13:00 – 15:00	Asymptomatic Gene Carrier Studies Working Group	Emerald Room	1st
13:00 – 16:00	ENCALS (closed meeting)	E107/E108	1st
16:00 – 18:30	Project MinE (closed meeting)	E107/E108	1st
15:00 – 18:00	Registration International Symposium	Entrance G	GF
15:00 – 18:00	Speaker Room	G001/G002	GF
16:30 – 18:00	ALS App Europe Initiative	E102	1st
17:30 – 19:00	Welcome Networking Reception	Diamond Lounge	GF

Wednesday 9 December

07:00 – 17:30	Registration International Symposium	Entrance G	GF
07:00 – 18:00	Speaker Room	G001/G002	GF
08:30 – 10:00	Symposium Joint Opening Session	See programme	
10:00 – 10:30	Refreshments and Networking	See programme	
10:00 – 10:30	Exhibitors	See programme	
10:30 – 12:30	Symposium Sessions 2A/2B	See programme	
12:30 – 14:00	Lunch and Networking	See programme	
12:30 - 14:00	Exhibitors	See programme	
12:30 – 14:00	INARC Lunch Meeting (closed meeting)	Emerald Room	1st
14:00 – 15:30	Symposium Sessions 3A/3B/3C	See programme	
15:30 – 16:00	Refreshments and Networking	See programme	
15:30 – 16:00	Exhibitors	See programme	
16:00 – 17:30	Symposium Sessions 4A/4B/4C	See programme	
17:45 – 19:30	Poster Session A	See programme	

Thursday 10 December

07:00 – 17:30	Registration International Symposium	Entrance G	GF
07:00 – 18:00	Speaker Room	G001/G002	GF
07:15 – 08:15	Network of Excellence for ALS Member Meeting (closed meeting)		
08:30 – 10:00	Symposium Sessions 5A/5B/5C	See programme	
10:00 – 10:30	Refreshments and Networking	See programme	
10:00 – 10:30	Exhibitors	See programme	
10:30 – 12:30	Symposium Sessions 6A/6B/6C	See programme	
12:30 – 14:00	Lunch and Networking	See programme	
12:30 - 14:00	Exhibitors	See programme	

12:30 – 14:00	Healey & AMG Center for ALS Networking Lunch (closed meeting)	Emerald Room	1st
14:00 – 15:30	Symposium Sessions 7A/7B/7C	See programme	
15:30 – 16:00	Refreshments and Networking	See programme	
15:30 – 16:00	Exhibitors	See programme	
16:00 – 17:30	Symposium Sessions 8A/8B/8C	See programme	
17:30 – 19:30	Poster Session B	See programme	

Friday 11 December

07:00 – 12:00	Registration International Symposium	Entrance G	GF
07:30 – 12:00	Speaker Room	G001/G002	GF
07:00 – 08:30	Sponsored Breakfast Session	E103-E108	1st
08:30 – 10:00	Symposium Sessions 9A/9B	See programme	
10:00 – 10:30	Refreshments, Networking and Exhibitors	See programme	
10:00 – 10:30	Exhibitors	See programme	
10:30 – 12:30	Symposium Sessions 10A/10B/10C	See programme	
12:30 – 13:30	Lunch and Networking	See programme	
12:30 - 13:30	Exhibitors	See programme	
13:30 – 15:20	Symposium Joint Closing Session	See programme	

Floorplans – Ground floor (GF)



Activity/Session	Location
Main entrance to event	G
Registration Inside left of entrance	G
Speaker Room/Conference Office	G001/G002/G003
Exhibition	Onyx Lounge
Posters	Europe Foyer 1 & 2
Session A	Auditorium
Session B	Forum
Patient Fellows Room	E001
Refreshments	Auditorium Lounge/Forum Lounge
Diamond Lounge/Onyx Lounge	

Floorplans – First floor (1st)



Activity/Session	Location
Session C	E103 – E108
Satellite Meeting Room	Emerald Room
Satellite Meeting Room	E102
Satellite Meeting Room	G101
Refreshments	Upper Lounge/Emerald Lounge/Topaz Lounge

Exhibitors

Please visit our exhibitors, located in the Onyx Lounge.

More information can be found on our website, symposium.mndassociation.org, and on the Symposium App































Supporters

With grateful thanks to the following supporters of the 37th International Symposium on ALS/MND.

Notes

MND Association

38th International Symposium on ALS/MND

Dublin 2027

Join us in Dublin, Ireland
6 – 8 December 2027



For further information please contact:

Tel: +44 (0) 1604 611837
Email: symposium@mndassociation.org
Email: abstracts@mndassociation.org

mndassociation.org
symposium.mndassociation.org

Symposium Host:

Irish Motor Neurone Disease Association